The Epigenetic-metabolic Interplay in Gliomagenesis

Overview

Journal Open Biol

Specialties Biology
Cell Biology
Molecular Biology

Date 2022 Apr 6

PMID 35382567

Authors

Bismi Phasaludeen

Bright Starling Emerald

Suraiya Anjum Ansari

Affiliations

Soon will be listed here.

Abstract

Although tumourigenesis occurs due to genetic mutations, the role of epigenetic dysregulations in cancer is also well established. Epigenetic dysregulations in cancer may occur as a result of mutations in genes encoding histone/DNA-modifying enzymes and chromatin remodellers or mutations in histone protein itself. It is also true that misregulated gene expression without genetic mutations in these factors could also support tumour initiation and progression. Interestingly, metabolic rewiring has emerged as a hallmark of cancer due to gene mutations in specific metabolic enzymes or dietary/environmental factors. Recent studies report an intricate cross-talk between epigenetic and metabolic reprogramming in cancer. This review discusses the role of epigenetic and metabolic dysregulations and their cross-talk in tumourigenesis with a special focus on gliomagenesis. We also discuss the role of recently developed human embryonic stem cells/induced pluripotent stem cells-derived organoid models of gliomas and how these models are proving instrumental in uncovering human-specific cellular and molecular complexities of gliomagenesis.

Citing Articles

RAB32 promotes glioma cell progression by activating the JAK/STAT3 signaling pathway.

Zhang S, Jiang X, Wei Q, Huang L, Huang Z, Zhang L J Int Med Res. 2024; 52(12):3000605241282384.

PMID: 39628429 PMC: 11615995. DOI: 10.1177/03000605241282384.

Gliomagenesis, Epileptogenesis, and Remodeling of Neural Circuits: Relevance for Novel Treatment Strategies in Low- and High-Grade Gliomas.

Grimi A, Bono B, Lazzarin S, Marcheselli S, Pessina F, Riva M Int J Mol Sci. 2024; 25(16).

PMID: 39201639 PMC: 11354416. DOI: 10.3390/ijms25168953.

Chromatin modifiers in human disease: from functional roles to regulatory mechanisms.

Nie Y, Song C, Huang H, Mao S, Ding K, Tang H Mol Biomed. 2024; 5(1):12.

PMID: 38584203 PMC: 10999406. DOI: 10.1186/s43556-024-00175-1.

RNA-binding protein DHX9 promotes glioma growth and tumor-associated macrophages infiltration via TCF12.

Liu L, Zhou X, Cheng S, Ge Y, Chen B, Shi J CNS Neurosci Ther. 2022; 29(4):988-999.

PMID: 36377508 PMC: 10018109. DOI: 10.1111/cns.14031.

The Significance of Promoter Methylation Status in Diffuse Glioma.

Jovanovic N, Lazarevic M, Cvetkovic V, Nikolov V, Kostic Peric J, Ugrin M Int J Mol Sci. 2022; 23(21).

PMID: 36361838 PMC: 9654114. DOI: 10.3390/ijms232113034.

References

Zhou W, Wahl D . Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance. Cancers (Basel). 2019; 11(9). PMC: 6770393. DOI: 10.3390/cancers11091231. View

Dyer M, Qadeer Z, Valle-Garcia D, Bernstein E . ATRX and DAXX: Mechanisms and Mutations. Cold Spring Harb Perspect Med. 2017; 7(3). PMC: 5334245. DOI: 10.1101/cshperspect.a026567. View

Gimm O, Armanios M, Dziema H, Neumann H, Eng C . Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res. 2001; 60(24):6822-5. View

Taylor K, Mackay A, Truffaux N, Butterfield Y, Morozova O, Philippe C . Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014; 46(5):457-461. PMC: 4018681. DOI: 10.1038/ng.2925. View

Zanders E, Svensson F, Bailey D . Therapy for glioblastoma: is it working?. Drug Discov Today. 2019; 24(5):1193-1201. DOI: 10.1016/j.drudis.2019.03.008. View

Xiao T, Hall H, Kizer K, Shibata Y, Hall M, Borchers C . Phosphorylation of RNA polymerase II CTD regulates H3 methylation in yeast. Genes Dev. 2003; 17(5):654-63. PMC: 196010. DOI: 10.1101/gad.1055503. View

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A . Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009; 118(4):469-74. DOI: 10.1007/s00401-009-0561-9. View

Muntean A, Hess J . Epigenetic dysregulation in cancer. Am J Pathol. 2009; 175(4):1353-61. PMC: 2751531. DOI: 10.2353/ajpath.2009.081142. View

Gill A . Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology. 2017; 72(1):106-116. DOI: 10.1111/his.13277. View

10.

Grubb 3rd R, Franks M, Toro J, Middelton L, Choyke L, Fowler S . Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007; 177(6):2074-9. DOI: 10.1016/j.juro.2007.01.155. View

11.

Vitucci M, Hayes D, Miller C . Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer. 2010; 104(4):545-53. PMC: 3049580. DOI: 10.1038/sj.bjc.6606031. View

12.

Michalowska I, Cwikla J, Prejbisz A, Kwiatek P, Szperl M, Michalski W . Mediastinal paragangliomas related to gene mutations. Kardiochir Torakochirurgia Pol. 2016; 13(3):276-282. PMC: 5071602. DOI: 10.5114/kitp.2016.62624. View

13.

Anastasaki C, Wegscheid M, Hartigan K, Papke J, Kopp N, Chen J . Human iPSC-Derived Neurons and Cerebral Organoids Establish Differential Effects of Germline NF1 Gene Mutations. Stem Cell Reports. 2020; 14(4):541-550. PMC: 7160375. DOI: 10.1016/j.stemcr.2020.03.007. View

14.

Baker S, Ellison D, Gutmann D . Pediatric gliomas as neurodevelopmental disorders. Glia. 2015; 64(6):879-95. PMC: 4833573. DOI: 10.1002/glia.22945. View

15.

Tagami H, Ray-Gallet D, Almouzni G, Nakatani Y . Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis. Cell. 2004; 116(1):51-61. DOI: 10.1016/s0092-8674(03)01064-x. View

16.

Erez A, DeBerardinis R . Metabolic dysregulation in monogenic disorders and cancer - finding method in madness. Nat Rev Cancer. 2015; 15(7):440-8. DOI: 10.1038/nrc3949. View

17.

Baysal B, Ferrell R, Willett-Brozick J, Lawrence E, Myssiorek D, Bosch A . Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000; 287(5454):848-51. DOI: 10.1126/science.287.5454.848. View

18.

Fieuw A, Kumps C, Schramm A, Pattyn F, Menten B, Antonacci F . Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. Int J Cancer. 2011; 130(11):2599-606. DOI: 10.1002/ijc.26317. View

19.

Joseph J, Jensen M, Ilkayeva O, Palmieri F, Alarcon C, Rhodes C . The mitochondrial citrate/isocitrate carrier plays a regulatory role in glucose-stimulated insulin secretion. J Biol Chem. 2006; 281(47):35624-32. DOI: 10.1074/jbc.M602606200. View

20.

Munoz-Pinedo C, Gonzalez-Suarez E, Portela A, Gentilella A, Esteller M . Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine. Cancer Res. 2013; 73(14):4185-9. DOI: 10.1158/0008-5472.CAN-13-0512. View